This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Danielle Dettling
Senior Director, Pre-Clinical Pharmacology at Maverick Therapeutics


Danielle Dettling is Senior Director of Preclinical Pharmacology at Maverick Therapeutics, where she leads program selection for Maverick’s COBRA platform.  Together with her team she develops strategies for pre-clinical characterization for IND-enabling studies on COBRA lead molecules, and validation through toxicology studies to support therapeutic development in the solid tumor arena.  Currently this includes the 2 COBRA Clinical Leads MVC-101, MVC-280 and subsequent pre-clinical programs.  Danielle joined Maverick shortly after the company’s formation in 2017, and has over 10 years experience in the biotechnology and pharmaceutical industry, with specific expertise in novel biologic therapeutics for hematological and solid tumor indications, as well as therapeutics outside of the Oncology space.  Prior to joining Maverick, Danielle was program lead for CD3 bispecific and CAR-T programs targeting hematological malignancies at the Pfizer Rinat site in San Francisco, and was additionally involved in computational assessment of optimal therapeutic targeting for many therapeutic antibody programs.    

Agenda Sessions

  • The Conditionally Activated COBRA Demonstrates an Improved Therapeutic Window over Conventional T-cell Engagers in the Solid Tumor Space